The Oncology Institute, Inc. Common Stock (TOI) is a publicly traded Healthcare sector company. As of May 21, 2026, TOI trades at $4.10 with a market cap of $399.93M and a P/E ratio of -11.64. TOI moved +2.32% today. Year to date, TOI is +7.14%; over the trailing twelve months it is +51.08%. Its 52-week range spans $0.13 to $4.88. Analyst consensus is strong buy with an average price target of $7.00. Rallies surfaces TOI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Oncology Institute Guides Q1 Revenue $143.23M, Raises Full-Year Estimate to $647.84M: The Oncology Institute Inc forecasts Q1 2026 revenue of $143.23 million and an EPS loss of $0.08, with full-year estimates rising to $647.84 million revenue and a $0.23 EPS deficit. Analysts lifted full-year 2026 revenue projections by 1.8% over 90 days following the previous quarter’s 1.56% revenue beat and 33.33% EPS outperformance.
| Metric | Value |
|---|---|
| Price | $4.10 |
| Market Cap | $399.93M |
| P/E Ratio | -11.64 |
| EPS | $-0.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.88 |
| 52-Week Low | $0.13 |
| Volume | 1.30K |
| Avg Volume | 0 |
| Revenue (TTM) | $545.76M |
| Net Income | $-43.51M |
| Gross Margin | 0.00% |
4 analysts cover TOI: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.00.